Baylor Health Care SystemAbout B
Research: From moving better to recovering faster, here's what we're studying. 
Need something? Call us: 1.800.4BAYLOR(1.800.422.9567)
Text Size:

Research Studies 

Find the trial that interests you in 3 easy steps.

Step 1: Please choose a condition.

Step 2: Select the appropriate diagnosis from the list below. You will then be presented with a listing of the clinical trials taking place at Baylor.

Step 3: Optionally, select a facility.

  • Prospective Cohort Study of BRCA1 and BRCA2 Mutation Carriers and Non-Carriers with Compelling Family History (UPENN PROSE study)
  • Risk Factor Analysis of Hereditary Breast and Ovarian Cancer
  • Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone With or Without Exemestane in Postmenopausal Women With ER+ Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
  • A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
  • A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients With Metastatic Breast Cancer
  • A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer
  • A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer
  • Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy
  • Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer
  • A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women With Stage 0, I, or II Breast Cancer
  • A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
  • Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
  • A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer
  • The BEACON Study (Breast Cancer Outcomes With NKTR-102)
  • Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer
  • Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
  • Pilot Safety and Blood Immune Cell Transcriptional Profiling Study of Weekly Nab Paclitaxel Plus Anakinra in Metastatic Breast Cancer Patients